« Return to News | Drug Sponsors | CROs/Service Providers

Warnex completes sale of bioanalytical services to CRO Biotrial

Monday, December 17, 2012 11:06 AM

Warnex, a life sciences company, has successfully completed the sale of its bioanalytical services division to Biotrial Research, a privately-owned CRO headquartered in France.

A special resolution approving the transaction was adopted with the support of over 96.3% of the votes cast by shareholders at the annual and special meeting of shareholders held on December 10, 2012.

"With the completion of this transaction, the board will explore possible strategic alternatives for Warnex's remaining assets, which consist primarily of cash and receivables, for the benefit of all our shareholders," said Michael Singer, chairman of the board of directors, Warnex. "We expect to quickly identify opportunities, if any, which may range from a possible wind-up of Warnex and cash distribution to shareholders to a variety of possible mergers and acquisitions alternatives. We will report back to our shareholders as expeditiously as possible."

As a result of the closing of the transaction, the listing of Warnex's common shares is expected to be transferred from the TSX Venture Exchange to the NEX. Further details will be announced by Warnex at a later date.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.